4.5 Review

Engineered Live Biotherapeutics: Progress and Challenges

Journal

BIOTECHNOLOGY JOURNAL
Volume 15, Issue 10, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/biot.202000155

Keywords

engineered commensal bacteria; human diseases; live biotherapeutics; phages; synthetic microbial consortia

Funding

  1. National Key R&D Program of China [2019YFA09006700, 2019YFA0904400]
  2. National Natural Science Foundation of China [31971513]
  3. Shenzhen Institute of Synthetic Biology [DWKF20190001]
  4. SIAT Innovation Program for Excellent Young Researchers [Y8G023]
  5. China Postdoctoral Science Foundation [2019M663166]
  6. IDG-McGovern Institute for Brain Research
  7. School of Pharmaceutical Sciences at Tsinghua University

Ask authors/readers for more resources

The human microbiome plays an important role in human health, from metabolism to immunity. In the last few decades, advances in synthetic biology have enabled scientists to design and engineer live microorganisms for therapeutic purposes. In this review, major strategies for manipulating the microbiome are outlined, which include three emerging areas with promising therapeutic applications: engineered commensal bacteria, synthetic microbial consortia, and targeted modulation by phages. Furthermore, the applications of engineered live biotherapeutics in treating a variety of human diseases, including pathogenic infections, metabolic disorders, inflammatory bowel disease, and colorectal cancer, are highlighted. Finally, an overview of the challenges and opportunities in the future development of engineered live biotherapeutics is provided.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available